{
    "clinical_study": {
        "@rank": "80787", 
        "arm_group": [
            {
                "arm_group_label": "Myrbetriq/Detrol LA sequence group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive Myrbetriq in the first treatment period then Detrol LA for the second treatment period."
            }, 
            {
                "arm_group_label": "Detrol LA/Mybetriq sequence group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive Detrol LA in the first treatment period then Myrbetriq for the second treatment period."
            }, 
            {
                "arm_group_label": "Myrbetriq/Myrbetriq sequence group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive Myrbetriq in both treatment periods."
            }, 
            {
                "arm_group_label": "Detrol LA/Detrol LA sequence group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive Detrol LA in both treatment periods."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess tolerability of Myrbetriq compared to Detrol LA in\n      the treatment of subjects with Overactive Bladder (OAB). This study will also assess patient\n      preference, safety and tolerability of Myrbetriq and Detrol LA in subjects with symptoms of\n      OAB as well as the impact of treatment on micturition frequency and incontinence episodes."
        }, 
        "brief_title": "A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq\u00ae and Detrol\u00ae LA in Subjects With Overactive Bladder (OAB)", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder (OAB)", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "detailed_description": {
            "textblock": "The study will comprise of two double-blind treatment periods with a wash-out period in\n      between. Subjects will receive a placebo during this time period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is willing and able to complete the micturition diary and questionnaires\n             correctly.\n\n          -  Subject has symptoms of OAB (urinary frequency and urgency with or without\n             incontinence) for greater than or equal to 3 months prior to Screening.\n\n          -  Subject must be treatment-na\u00efve to pharmaceutical agents for OAB.\n\n          -  Female subject must not donate ova starting at Screening and throughout the study\n             period, and for 30 days after the final study drug administration.\n\n          -  Male subject must not donate sperm starting at Screening and throughout the study\n             period and for at least 30 days after final study drug administration.\n\n          -  Subject agrees not to participate in another interventional study from the time of\n             screening until the final study visit.\n\n          -  Inclusion Criteria assessed at Visit 2 (Week 0) based on the 3-day micturition diary:\n\n               -  Subject continues to meet all inclusion criteria of Visit 1.\n\n               -  Subject must experience at least 3 episodes of urgency (grade 3 or 4) during the\n                  3 day micturition diary.\n\n               -  Subject must experience an average of greater than or equal to 8\n                  micturitions/day on the 3 day micturition diary\n\n        Exclusion Criteria:\n\n          -  Female subject who is lactating or is intending to breastfeed during the study period\n             and for 30 days after the final study visit.\n\n          -  The subject has clinically significant bladder outlet obstruction (BOO) posing a risk\n             of urinary retention.\n\n          -  Subject has significant stress incontinence or mixed stress/urgency incontinence\n             where stress is the predominant factor.\n\n          -  Subject has evidence of Urinary Tract Infection (UTI) (urine culture greater than\n             100,000 cfu/mL) as assessed at Screening (Visit 1).  The subject can be rescreened\n             after successful treatment of the UTI (confirmed by a laboratory result of negative\n             urine culture).\n\n          -  Subject has a neurological cause for detrusor overactivity (e.g., neurogenic bladder,\n             diabetic neuropathy or systemic or central neurological disease such as multiple\n             sclerosis and Parkinson's disease).\n\n          -  Subject has an indwelling catheter or practices intermittent self-catheterization.\n\n          -  Subject has a chronic inflammatory condition such as interstitial cystitis, bladder\n             stones, previous pelvic radiation therapy, or previous or current malignant disease\n             of the pelvic organs (i.e., within the confines of the pelvis including the bladder\n             and rectum in both sexes and the uterus, ovaries, and fallopian tubes in females); or\n             of the lower gastrointestinal tract.\n\n          -  Subject has uncontrolled narrow angle glaucoma, urinary or gastric retention, severe\n             colitis ulcerosa, toxic megacolon, myasthenia gravis, polio or any other medical\n             condition which makes the use of anticholinergics contraindicated.\n\n          -  Subject has received intravesical injection in the past 12 months with botulinum\n             toxin, resiniferatoxin, or capsaicin.\n\n          -  Subject has received invasive treatment including electro-stimulation therapy.\n\n          -  Subject is receiving a bladder training program or pelvic floor exercises which\n             started or has changed less than 30 days prior to Screening.\n\n          -  Subject has hepatic impairment defined as Child-Pugh Class A, B or C.\n\n          -  Subject has severe renal impairment defined as creatinine clearance less than 30\n             mL/min. A subject with End Stage Renal Disease or undergoing dialysis is also not a\n             candidate for the study.\n\n          -  Subject has severe uncontrolled hypertension, which is defined as a sitting systolic\n             blood pressure greater than or equal 180 mmHg and/or diastolic blood pressure greater\n             than or equal 110 mmHg.\n\n          -  Subject has evidence of QT prolongation on electrocardiogram (ECG) defined as QTcF\n             greater than 450 msec for males, QTcF greater than 470 msec for females or a known\n             history of QT prolongation.\n\n          -  Subject has a serum creatinine greater than 150 \u00b5mol/L, or aspartate aminotransferase\n             (AST) or alanine aminotransferase (ALT) greater than 2x upper limit of normal (ULN),\n             or \u03b3-GT greater than 3x ULN and considered clinically significant.\n\n          -  Subject has a hypersensitivity to any components of Myrbetriq (mirabegron), other\n             \u03b2-AR agonists, tolterodine or other antimuscarinic agents, or any of the inactive\n             ingredients.\n\n          -  Subject has been treated with an experimental device within 30 days or received an\n             investigational agent within 30 days prior to Screening.\n\n          -  Subject has a concurrent malignancy or history of any malignancy (within the past 5\n             years), except non-metastatic basal or squamous cell carcinoma of the skin that has\n             been treated successfully.\n\n          -  Subject with current history of alcohol and/or drug abuse.\n\n          -  Subject is involved in the conduct of the study as an employee of the Astellas group,\n             third party associated with the study, or the study site team.\n\n          -  Exclusion Criteria assessed at Visit 2 (Week 0):\n\n               -  Subject fulfills any exclusion criteria at Visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138747", 
            "org_study_id": "178-MA-1001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Myrbetriq/Detrol LA sequence group", 
                    "Detrol LA/Mybetriq sequence group", 
                    "Myrbetriq/Myrbetriq sequence group"
                ], 
                "description": "Oral", 
                "intervention_name": "Myrbetriq", 
                "intervention_type": "Drug", 
                "other_name": [
                    "YM178,", 
                    "Mirabegron"
                ]
            }, 
            {
                "arm_group_label": [
                    "Myrbetriq/Detrol LA sequence group", 
                    "Detrol LA/Mybetriq sequence group", 
                    "Detrol LA/Detrol LA sequence group"
                ], 
                "description": "Oral", 
                "intervention_name": "Detrol LA", 
                "intervention_type": "Drug", 
                "other_name": "tolterodine ER"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tolterodine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Overactive bladder (OAB)", 
            "Myrbetriq", 
            "Detrol LA"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq\u00ae and Detrol\u00ae LA in Subjects With Overactive Bladder (OAB)", 
        "overall_contact": {
            "email": "clintrials.info@us.astellas.com", 
            "last_name": "Astellas Pharma Global Development", 
            "phone": "800-888-7704", 
            "phone_ext": "5473"
        }, 
        "overall_official": {
            "affiliation": "Astellas Scientific & Medical Affairs, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Patient tolerability assessed by the Tolerability Scale of the Overactive Bladder-satisfaction (OAB-S) questionnaire", 
            "safety_issue": "No", 
            "time_frame": "At the end of each treatment period (Week 8 and Week 18)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138747"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The 5-point scale is composed of: strong preference for period 1, mild preference for period 1, no preference, mild preference for period 2, strong preference for period 2.", 
                "measure": "Patient preference from a 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "At the end of the second treatment period (Week 18)"
            }, 
            {
                "description": "Impact on daily living with Overactive Bladder (OAB); OAB control; Satisfaction with control; Overall assessment of Patient's fulfillment of OAB medication expectations; Overall assessment of interruption of day-to-day life due to OAB; Overall satisfaction with OAB medication; Overall assessment of willingness to continue OAB medication; Overall assessment of improvement in day-to-day life due to OAB medication", 
                "measure": "Scales of the OAB-S questionnaire", 
                "safety_issue": "No", 
                "time_frame": "At the end of each treatment period (Week 8 and Week 18)"
            }, 
            {
                "measure": "Change from baseline in number of incontinence episodes per 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to end of each treatment period (Week 8 and Week 18)"
            }, 
            {
                "measure": "Change from baseline in number of micturitions per 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to end of each treatment period (Week 8 and Week 18)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}